Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KMT2A | Q03164 | 5/20 | 0.59 |
| ▸ | TET3 | O43151 | 2/20 | 0.59 |
| ▸ | FBXL19 | Q6PCT2 | 2/20 | 0.59 |
| ▸ | CXXC5 | Q7LFL8 | 2/20 | 0.59 |
| ▸ | KDM2B | Q8NHM5 | 2/20 | 0.59 |
| ▸ | CXXC4 | Q9H2H0 | 2/20 | 0.59 |
| ▸ | KDM2A | Q9Y2K7 | 2/20 | 0.59 |
| ▸ | MEN1 | O00255 | 3/20 | 0.54 |
| ▸ | TSHR | P16473 | 2/20 | 0.53 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.53 |
| ▸ | ATM | Q13315 | 1/20 | 0.53 |
| ▸ | STS | P08842 | 2/20 | 0.50 |
| ▸ | TET1 | Q8NFU7 | 1/20 | 0.46 |
| ▸ | HSD11B1 | P28845 | 3/20 | 0.46 |
| ▸ | USP2 | O75604 | 1/20 | 0.45 |
| ▸ | HPGD | P15428 | 1/20 | 0.45 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.45 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.45 |
| ▸ | DRD2 | P14416 | 1/20 | 0.45 |
| ▸ | OPRD1 | P41143 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL191573 | 0.92 | KMT2A (0.53) | KMT2ATET3FBXL19CXXC5KDM2B | |
| SCHEMBL653532 | 0.90 | KMT2A (0.54) | KMT2ATET3FBXL19CXXC5KDM2B | |
| SCHEMBL654889 | 0.88 | KMT2A (0.53) | KMT2ATET3FBXL19CXXC5KDM2B | |
| SCHEMBL972474 | 0.88 | TSHR (0.65) | KMT2ATET3FBXL19CXXC5KDM2B | |
| SCHEMBL654744 | 0.87 | KMT2A (0.52) | KMT2ATET3FBXL19CXXC5KDM2B | |
| SCHEMBL28028621 | 0.87 | TSHR (0.56) | KMT2ATET3FBXL19CXXC5KDM2B | |
| SCHEMBL12988312 | 0.87 | TSHR (0.53) | KMT2ATET3FBXL19CXXC5KDM2B | |
| SCHEMBL396197 | 0.87 | TSHR (0.53) | KMT2ATET3FBXL19CXXC5KDM2B | |
| SCHEMBL12497627 | 0.86 | TSHR (0.47) | KMT2ATET3FBXL19CXXC5KDM2B | |
| SCHEMBL4431260 | 0.86 | KMT2A (0.51) | KMT2ATET3FBXL19CXXC5KDM2B |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 94 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3719018-B1 | PURINE AND DEAZAPURINE DERIVATIVES AS PHARMACEUTICAL COMPOUNDS | ASTEX THERAPEUTICS LTD (GB) | 2025-08-27 | — | — | EP | disclosed |
| CN-115485276-B | Deuterated AKT kinase inhibitors | 南京正大天晴制药有限公司 | 2024-05-31 | — | — | CN | disclosed |
| CN-117964620-A | AKT inhibitors | 南京正大天晴制药有限公司 | 2024-05-03 | — | — | CN | disclosed |
| CN-113272304-B | AKT inhibitors | 南京正大天晴制药有限公司 | 2024-03-29 | — | — | CN | disclosed |
| CN-110088093-B | Acyl sulfonamide nav1.7 inhibitors | 百时美施贵宝公司 | 2023-06-13 | — | — | CN | disclosed |
| CN-115485276-A | Deuterated AKT kinase inhibitors | 南京正大天晴制药有限公司 | 2022-12-16 | — | — | CN | disclosed |
| EP-3532462-B1 | ACYL SULFONAMIDE NAV1.7 INHIBITORS | BRISTOL MYERS SQUIBB CO (US) | 2021-10-13 | — | — | EP | disclosed |
| EP-3532462-B1 | ACYL SULFONAMIDE NAV1.7 INHIBITORS | BRISTOL MYERS SQUIBB CO (US) | 2021-10-13 | — | — | EP | disclosed |
| CN-113272304-A | AKT inhibitors | 南京正大天晴制药有限公司 | 2021-08-17 | — | — | CN | disclosed |
| EP-3421471-B1 | PURINE AND DEAZAPURINE DERIVATIVES AS PHARMACEUTICAL COMPOUNDS | ASTEX THERAPEUTICS LTD (GB) | 2021-05-26 | — | — | EP | disclosed |
| WO-2007044804-A2 | PIPERIDINE DERIVATIVES AND METHODS OF USE | CHEMOCENTRYX, INC. (US) | 2007-04-19 | — | — | WO | disclosed |
| US-20070088036-A1 | Piperidine derivatives and methods of use | CHEMOCENTRYX, INC. (US) | 2007-04-19 | — | — | US | disclosed |
| US-20070060592-A1 | heterocylic amines such as 2-(5-{3-[4-(4-Chloro-2-methyl-phenyl)-piperazin-1-yl]-propylidene}-5,11-dihydro-10-oxa-1-aza-dibenzo[a,d]cyclohepten-7-yl)-propan-2-ol, used for treating diseases associated with aberrant leukocyte recruitment and/or activation | MILLENNIUM PHARMACEUTICALS, INC. | 2007-03-15 | — | — | US | disclosed |
| WO-2006136829-A2 | PYRAZOLE DERIVATIVES AND THEIR USE AS PKA AND PKB MODULATORS | ASTEX THERAPEUTICS LIMITED (GB) | 2006-12-28 | — | — | WO | disclosed |
| EP-1688418-A2 | Chemokine receptor antagonists and methods of use thereof | MILLENNIUM PHARMACEUTICALS, INC. (US) | 2006-08-09 | — | — | EP | disclosed |
| US-20060128752-A1 | Chemical compounds | GLAXO GROUP LIMITED (GB) | 2006-06-15 | — | — | US | disclosed |
| WO-2006046024-A1 | ORTHO- CONDENSED PYRIDINE AND PYRIMIDINE DERIVATIVES (E. G. PURINES) AS PROTEIN KINASES INHIBITORS | ASTEX THERAPEUTICS LIMITED (GB) | 2006-05-04 | — | — | WO | disclosed |
| US-20050070549-A1 | Chemokine receptor antagonists and methods of use thereof | KYOWA HAKKO KOGYO CO., LTD. (JP) | 2005-03-31 | — | — | US | disclosed |
| EP-1448566-A2 | CHEMOKINE RECEPTOR ANTAGONISTS AND METHODS OF USE THEREOF | MILLENNIUM PHARMACEUTICALS, INC. (US) | 2004-08-25 | — | — | EP | disclosed |
| WO-2003045942-A2 | CHEMOKINE RECEPTOR ANTAGONISTS AND METHODS OF USE THEREOF | MILLENNIUM PHARMACEUTICALS, INC. (US) | 2003-06-05 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060128752-A1 | Chemical compounds | HTR7, NPSR1, TACR2 | KMT2A 3763/4885TET3 2851/4885FBXL19 1705/4885 |
| US-20050070549-A1 | Chemokine receptor antagonists and methods of use thereof | ACKR3, CXCR2, CCL11 | KMT2A 4640/4885TET3 4862/4885FBXL19 4671/4885 |
| US-20070088036-A1 | Piperidine derivatives and methods of use | CCR1, CCR3, CCR4 | KMT2A 4268/4885TET3 4570/4885FBXL19 3505/4885 |
| US-20070060592-A1 | heterocylic amines such as 2-(5-{3-[4-(4-Chloro-2-methyl-phenyl)-piperazin-1-yl]-propylidene}-5,11-dihydro-10-oxa-1-aza-dibenzo[a,d]cyclohepten-7-yl)-propan-2-ol, used for treating diseases associated with aberrant leukocyte recruitment and/or activation | THPO, NFATC1, HPGDS | KMT2A 1082/4885TET3 519/4885FBXL19 4839/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.